Arcus Biosciences Q2 2026 Results: Revenue Falls Without Last Year's License Catch-Up

Arcus Biosciences (NYSE: RCUS) reported Q2 2026 revenue of $41 million, down about 74% from $160 million a year earlier, and diluted EPS of -$0.72 versus $0.00 as reported. The company recorded a $91 million net loss, while cash, cash equivalents and marketable securities ended the June 30 quarter at $775 million; lower operating expenses did not offset the revenue decline.

Core Financial Results

Revenue fell primarily because Q2 2025 included a $143 million cumulative catch-up in license and development services revenue related to pausing etrumadenant development and Gilead returning its license. The 2026 quarter benefited from higher access-rights revenue following the expiration of Gilead option rights and increased revenue from programs optioned under the Taiho collaboration, but those items were insufficient to offset the prior-year comparison.

Total operating expenses declined by $31 million, reflecting lower R&D and G&A spending. However, revenue declined by $119 million, causing the operating loss to widen by $88 million.

All results are GAAP. R&D expenses declined as Arcus wound down domvanalimab studies and completed enrollment in the PRISM-1 trial, partly offset by increased activity in Phase 3 casdatifan studies. G&A expenses decreased primarily because of operational streamlining.

Casdatifan Becomes More Central as Anti-TIGIT Work Winds Down

Casdatifan, a HIF-2α inhibitor for clear cell renal cell carcinoma, is becoming the primary focus of Arcus’s oncology pipeline. The company announced collaborations with Bristol Myers Squibb, Summit Therapeutics and AVEO Oncology to test casdatifan in new combinations, while another collaboration involving an anti-PD-x/VEGF bispecific antibody is expected to begin in Q4 2026.

Arcus is pursuing casdatifan across first-line, second-line and later-line kidney cancer. The company also expects a $15 million milestone payment from Taiho Pharmaceutical in Q3 2026 following PEAK-1 enrollment in Japan.

Several clinical milestones are expected through 2027, with the most immediate readouts concentrated in the second half of 2026.

Research published in Nature found that casdatifan produced deep and sustained suppression of serum erythropoietin. Those biomarker changes correlated with higher response rates and longer progression-free survival, although the upcoming clinical readouts remain necessary to clarify the drug’s efficacy across treatment settings.

At the same time, Arcus and its partners are pulling back from anti-TIGIT development. Following the discontinuation of STAR-221 and STAR-121, Arcus and AstraZeneca will discontinue the Phase 3 PACIFIC-8 study. This wind-down is contributing to lower near-term R&D spending, although savings will be partly redirected toward casdatifan and the immunology portfolio.

Liquidity and Research Funding

Cash, cash equivalents and marketable securities declined by $235 million during the first six months of 2026, from $1.01 billion at December 31, 2025, to $775 million at June 30, 2026. Arcus attributed the decrease primarily to cash used in R&D activities.

Collaboration reimbursements also declined to $17 million from $33 million a year earlier. Arcus said this reflected Gilead-led activities representing a larger share of joint development costs and a shift toward programs funded entirely by Arcus, which could increase the company’s direct funding requirements even as reported expenses decline.

2026 Guidance

Management expects lower near-term R&D expenses as domvanalimab studies wind down and streamlining measures take effect. Those savings are expected to be partly offset by higher investment in casdatifan and small-molecule immunology programs.

With $58 million of GAAP revenue recognized in the first half, the full-year range implies approximately $7 million to $17 million in second-half revenue. Collaboration accounting and milestone timing may continue to make quarterly revenue uneven.

Recent Insider Transactions

Reported insider activity over the past six months included 79,040 shares purchased across nine transactions and 110,325 shares sold across four transactions. That produced net sales of 31,285 shares, with a reported net purchase and sale percentage of -0.10%; total insider holdings were 36.67 million shares.

The latest reported entries include two indirect sales by President Juan Carlos Jaen, one derivative-security exercise or conversion, and seven director stock grants. The values below are presented as reported and do not represent share counts.

The stock grants were compensation-related awards rather than open-market purchases. The reported sales and grants alone do not establish insiders’ views of the company’s prospects.

Risks Investors Need to Watch

• Casdatifan execution: Arcus’s strategy increasingly depends on casdatifan. Delays, safety issues or weaker efficacy data could affect several planned studies and combinations simultaneously.
• Cash consumption: Cash declined by $235 million during the first half, and management expects approximately $600 million at year-end. A broader or faster clinical development plan could alter the projected runway.
• Lower collaboration support: Reimbursements fell year over year as Arcus shifted toward more fully funded programs, increasing the amount of development spending borne directly by the company.
• Revenue volatility: Collaboration revenue depends on licensing events, option rights and development milestones. The $143 million prior-year catch-up shows why quarterly comparisons may not track underlying research progress.
• Pipeline concentration: The anti-TIGIT program wind-down reduces costs but leaves casdatifan and quemliclustat carrying more of the late-stage clinical burden.

Summary

Arcus’s Q2 2026 results reflected a difficult comparison with a large prior-year licensing item rather than growth in recurring commercial revenue. Cost reductions from program wind-downs and streamlining were not enough to prevent a wider operating loss, while cash continued to fund an expanding casdatifan strategy. The next major points to monitor are the second-half casdatifan readouts, PEAK-1 enrollment, the planned PEAK-20 launch and whether spending remains consistent with the projected runway through at least the second half of 2028.